E
Jasper Therapeutics, Inc. JSPR
$1.14 -$0.03-2.56% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$1.17
Volume
529,802
Avg Vol (90D)
1,345,996
Market Cap
$32.74M
Dividend & Yield
--
52-Week Range
$1.16 - $7.19
P/E (TTM)
--
EPS (TTM)
-$5.90
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
2/5/2026 - Globe Newswire
Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $20.29
1/14/2026 - Ticker Report
Jasper Therapeutics initiated with a Buy at Rodman & Renshaw
1/13/2026 - TipRanks Financial Blog
Jasper Therapeutics initiated with bullish view at Rodman & Renshaw
1/13/2026 - The Fly
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria - Slideshow
1/11/2026 - SeekingAlpha
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript
1/8/2026 - SeekingAlpha
Jasper Therapeutics, Inc. (JSPR) Discusses Updated Data from BEACON and Open-Label Extension Studies in Chronic Urticaria Transcript
1/8/2026 - Seeking Alpha: Transcripts
Jasper Therapeutics (JSPR) Sees Promising Results in Briquilimab Studies
1/8/2026 - GuruFocus
Jasper Therapeutics reports updated data from briquilimab studies
1/8/2026 - The Fly
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic ...
1/8/2026 - GuruFocus
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
1/8/2026 - Globe Newswire
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky
1/8/2026 - Simply Wall St
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of ...
1/7/2026 - GuruFocus
Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO
1/7/2026 - TipRanks Financial Blog
Jasper Therapeutics appoints new CEO
1/7/2026 - Seeking Alpha - Healthcare
Jasper Therapeutics appoints new CEO
1/7/2026 - SeekingAlpha.com: All News
Jasper Therapeutics says Jeet Mahal to succeed Ronald Martell as CEO
1/7/2026 - The Fly
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
1/7/2026 - Globe Newswire
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 88.6% in December
12/28/2025 - MarketBeat
15.4% of TMED Holdings Seeing Recent Insider Buys
12/22/2025 - ETF Channel
Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data - Slideshow
12/4/2025 - SeekingAlpha
Penny Stocks To Watch Now - December 2nd
12/4/2025 - MarketBeat
Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript
12/2/2025 - SeekingAlpha
Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript
12/2/2025 - Seeking Alpha: Transcripts
Jasper Therapeutics Inc To Host an Investor Webinar Meeting Transcript
12/2/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$90.51M
EBIT (TTM)
-$91.52M
Net Income (TTM)
-$91.02M
Balance Sheet
Total Assets (Q)
$57.47M
Total Debt (Q)
$1.70M
Total Liabilities (Q)
$45.90M
Book Value Per Share (Q)
$0.4135
Cash Flow
Cash from Operations (TTM)
-$76.43M
Cash from Investing (TTM)
-$71.00K
Cash from Financing (TTM)
$34.90M
Net Change in Cash (TTM)
-$41.60M
Filings
Filing Date
Monday, November 10, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.59
7-Day Total Return
-17.39%
30-Day Total Return
-37.71%
60-Day Total Return
-36.31%
90-Day Total Return
-52.50%
Year to Date Total Return
-38.04%
1-Year Total Return
-81.61%
2-Year Total Return
-93.60%
3-Year Total Return
-93.77%
5-Year Total Return
-98.90%
52-week Low
Feb 12, 2026 - $1.16
52-week High
Jul 03, 2025 - $7.19
Valuation
Market Cap
$32.74M - Nano Cap
Enterprise Value
-$16.45M
Price/Sales (TTM)
--
Price/Book (Q)
2.83
Dividends and Shares
Shares Outstanding
16.64M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
jaspertx.com
Phone Number
650 549 1400
Address
2200 Bridge Pkwy
Redwood City, CA 94065
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product... more
NASDAQ 02/13/2026 4:00PM Eastern Quotes delayed